Skip to main content
OpenTrials

Clinical trial condition

Hemorrhagic Disorders

Explore clinical trials studying Hemorrhagic Disorders. Study availability and eligibility vary by location and protocol.

4,580 public trials 828 recruiting studies
Refine in advanced search Browse all conditions

Hemorrhagic Disorders trial results

Active, Not Recruiting

Evaluating Effectiveness and Long Term Safety of Damoctocog Alfa Pegol in Patients, Who Have Been Diagnosed With Hemophilia A

NCT03932201

Conditions
Blood Coagulation Disorders, Blood Coagulation Disorders, Inherited, Coagulation Protein Disorders, +6 more
Locations
  • South Alabama Medical Science Foundation Mobile, Alabama, United States
  • Banner MD Anderson Cancer Center Phoenix, Arizona, United States
  • University California Davis Davis, California, United States
  • Orthopaedic Hospital DBA Orthopaedic Institute for Children Los Angeles, California, United States
View all 29 locations
View Trial Details
Active, Not Recruiting

Study to Learn More About the Safety of Drug Jivi Over a Long Period of Time in Previously Treated Patients With Hemophilia A (Bleeding Disorder Resulting From a Lack of FVIII) Who Are Receiving Jivi Regularly at Their Treating Doctors to Prevent Bleeding

NCT04461639

Conditions
Blood Coagulation Disorders, Blood Coagulation Disorders, Inherited, Coagulation Protein Disorders, +6 more
Locations
  • Many Locations Multiple Locations, Austria
  • Many Locations Multiple Locations, Germany
  • Many Locations Multiple Locations, Greece
  • Many Locations Multiple Locations, Italy
View Trial Details
Active, Not Recruiting

Early Check: Expanded Screening in Newborns

NCT03655223

Conditions
17 Alpha-Hydroxylase Deficiency, 3-Hydroxy-3-Methylglutaric Aciduria, 3-Hydroxy-3-Methylglutaryl-CoA Lyase Deficiency, +456 more
Locations
  • RTI International Research Triangle Park, North Carolina, United States
View Trial Details
Active, Not Recruiting

Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

NCT04162210

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • GSK Investigational Site Tucson, Arizona, United States
  • GSK Investigational Site Pueblo, Colorado, United States
  • GSK Investigational Site Detroit, Michigan, United States
  • GSK Investigational Site Omaha, Nebraska, United States
View all 136 locations
View Trial Details
Active, Not Recruiting

Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Nirogacestat, Pomalidomide, and Dexamethasone in Participants With RRMM

NCT07150104

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • GSK Investigational Site Salvador, Estado de Bahia, Brazil
  • GSK Investigational Site Porto Alegre, Rio Grande do Sul, Brazil
  • GSK Investigational Site Halifax, Nova Scotia, Canada
  • GSK Investigational Site Villejuif, France
View Trial Details
Active, Not Recruiting

Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Isatuximab in Participants With RRMM

NCT07217184

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • GSK Investigational Site Atlanta, Georgia, United States
  • GSK Investigational Site Boston, Massachusetts, United States
  • GSK Investigational Site Grand Rapids, Michigan, United States
  • GSK Investigational Site Madison, Wisconsin, United States
View all 19 locations
View Trial Details

Related conditions